P/B
4,5
NewAmsterdam Pharma
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
$2.8B
Market Cap • 9/28/2026
2019
(7 years)
Founded
2022
(4 years ago)
IPO
NASDAQ
Listing Exchange
Netherlands
Country
Valuation
P/S
395,8
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
5,2
EPS
—
Market Cap
Market Cap
2,8B
EV
2,2B
EV/Revenue
306,8
EV/EBITDA
-8,9
EV/EBIT
-8,9
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-1,5%
Total Yield
-1,5%
Payout
0%
Retained Earnings
-875M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
-1846,3%
Capex/Revenue
3,7%
Capex/D&A
72%
Capex/OCF
-0,2%
SBC/OCF
—
% PPE
0,1%
% Goodwill
0%
ROE
—
ROIC
—
Leverage
N.D./EBITDA
2,6
Debt/Equity
0%
Current Ratio
9
Quick Ratio
8,7
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!